科伦药业新加坡 · Kelun Pharma

科伦药业新加坡 · Kelun Pharma 科伦新加坡，致力于将前沿科研成果转化为科学可靠、日常适用的健康解决方案。
从麦角硫因出发，我们关注身体状态维护、功能活力支持以及抗衰等长期健康目标，以严谨标准推动营养科技创新，持续推出值得信赖的健康产品。
用科学探索生命可能，用专业守护每一份健康。

During his recent visit to Singapore, Liu Gexin, Group Chairman of Sichuan Kelun Pharmaceutical Co., Ltd., met with the ...
02/05/2026

During his recent visit to Singapore, Liu Gexin, Group Chairman of Sichuan Kelun Pharmaceutical Co., Ltd., met with the leadership of Economic Development Board (EDB) and JTC Corporation (JTC) to share Kelun’s strategic vision and explore potential investments in Singapore.

The discussions with JTC and EDB focused on Kelun’s proposed initiatives in pharmaceutical manufacturing, healthcare innovation, and high-tech industrial development. As one of China’s leading pharmaceutical groups, Kelun brings strong capabilities in large-scale manufacturing, R&D, and global distribution.

During the meetings, Chairman Liu outlined Kelun’s interest in leveraging Singapore as a regional hub for advanced healthcare and life sciences, supported by the country’s robust regulatory framework, talent pool, and international connectivity. Both EDB and JTC shared insights on Singapore’s ecosystem, including opportunities for collaboration in areas such as biopharmaceutical production, innovation partnerships, and industrial infrastructure development.

Chairman Liu also shared Kelun’s strategic vision of establishing a regional platform in Singapore to support its international expansion, including potential investments in R&D, production capabilities, and innovation partnerships. Kelun is one of China’s leading pharmaceutical groups, with strong capabilities in large-scale manufacturing, research and development, and global supply chain operations.

Kelun’s proposed investments have the potential to contribute meaningfully to Singapore’s ambitions as a global hub for advanced manufacturing and biomedical sciences. Both sides expressed their commitment to further discussions aimed at translating these initiatives into concrete investment projects and long-term partnerships.

Two years ago in 2024, some Singaporeans visited Kelun Pharmaceuticals HQ to better understand Kelun’s pharmaceutical re...
10/04/2026

Two years ago in 2024, some Singaporeans visited Kelun Pharmaceuticals HQ to better understand Kelun’s pharmaceutical research capabilities and advanced bioscience manufacturing ecosystem.

That visit marked the beginning of a deeper engagement.

Over the past two years, we have worked closely with Singapore team — through multiple discussions, site visits, and strategic exchanges — to explore how Singapore can serve as a regional and global platform for Kelun’s growth. These efforts were focused not just on market entry, but on positioning Singapore as a base for innovation, partnerships, and international expansion.

Today, we are seeing the fruits of that journey.

Kelun is now planning their move into Singapore, with the intention of establishing our International Headquarters (IHQ) here. This reflects strong confidence in Singapore’s ecosystem — from regulatory excellence and talent pool, to its role as a gateway to ASEAN and beyond.

This milestone is not the result of a single meeting, but the culmination of sustained effort, trust-building, and alignment of vision between Singapore and one of China’s leading pharmaceutical and biotech companies.

We look forward to the next phase — supporting Kelun’s establishment in Singapore and building a strong life sciences partnership that contributes to innovation, healthcare advancement, and regional growth.

It was a great privilege to host senior officers from the Singapore Economic Development Board on their recent visit to ...
10/04/2026

It was a great privilege to host senior officers from the Singapore Economic Development Board on their recent visit to Kelun Biotech.

During the visit, the delegation had the opportunity to tour Kelun’s advanced life sciences laboratories and bioscience manufacturing facilities. The team gained deeper insights into the company’s R&D capabilities, innovation pipeline, and large-scale production systems that support global healthcare needs.

This exchange reflects the growing collaboration between Singapore and leading international life sciences companies. As Singapore continues to strengthen its position as a regional hub for biomedical sciences, partnerships like these play an important role in fostering innovation, investment, and talent development.

We look forward to further discussions and potential collaborations that can bring cutting-edge biotech solutions to Singapore and the wider ASEAN region.

Colleagues from Kelun Pharmaceutical’s headquarters were recently in Singapore to explore potential sites for expansion,...
21/03/2026

Colleagues from Kelun Pharmaceutical’s headquarters were recently in Singapore to explore potential sites for expansion, including land parcels and high-tech manufacturing facilities under the purview of the Jurong Town Corporation.

The visit provided a comprehensive understanding of Singapore’s advanced industrial infrastructure, regulatory environment, and strong support for pharmaceutical and biopharmaceutical manufacturing. Discussions also highlighted Singapore’s position as a strategic hub for regional production, innovation, and supply chain integration.

This recce marks an important step towards evaluating Singapore as a potential base for Kelun’s future high-value manufacturing and internationalisation efforts.

Colleagues from Kelun Pharma’s Singapore office had a highly productive and engaging meeting with friends from EDB and T...
21/03/2026

Colleagues from Kelun Pharma’s Singapore office had a highly productive and engaging meeting with friends from EDB and Tsinghua Medicine in Chengdu.

The discussion provided valuable insights into the evolving pharmaceutical landscape in China, including key trends in innovation, regulatory developments, and opportunities for cross-border collaboration.

Both sides exchanged perspectives on advancing R&D capabilities, strengthening industry partnerships, and exploring pathways to bring innovative therapies to broader markets. The dialogue also highlighted the growing importance of Singapore as a strategic hub for regional expansion and internationalisation.

We look forward to deepening these connections and translating these discussions into meaningful collaborations in the near future.

🌏 Kelun Pharmaceutical × Singapore Economic Development Board: Joining Hands to Usher in a New Chapter of Internationali...
19/03/2026

🌏 Kelun Pharmaceutical × Singapore Economic Development Board: Joining Hands to Usher in a New Chapter of Internationalization

📅 On February 25, 2026, Mr. Hong Yong'an, Deputy Director of Greater China at the Singapore Economic Development Board (EDB), and his delegation visited Kelun Group's headquarters and held an in-depth strategic exchange meeting with Kelun Group's senior management team, including Vice Presidents Lai Degui, Feng Hao, and Wu Zhonghua.

🔍 From Site Visit to Strategic Consensus

The afternoon's exchange began with a site visit to the Xindu base, followed by a lively discussion on "Kelun's Future in Singapore over the Next 3-5 Years":

✅ Grand Blueprint: Vice President Lai Degui elaborated on Kelun's international headquarters center construction plan;

✅ Industrial Implementation: Mu Chunlei, General Manager of Kelun Yongnian Big Health, shared the construction plan for the Singapore Big Health factory, outlining a production layout driven by both health products and pharmaceuticals;

✅ Innovation Engine: Shen Li, Deputy Director of the Pharmaceutical Research Institute, introduced Kelun's cutting-edge R&D product pipeline, showcasing its strong innovative capabilities.

💡 Policy Empowerment, Win-Win Future
Deputy Director-General Hong Yong'an and Director Hao Tian of the Singapore Economic Development Board (EDB) provided a detailed overview of Singapore's successful implementation cases and exclusive policy support in the pharmaceutical and healthcare sectors, offering Kelun a solid foundation of confidence and guidance for its overseas expansion.

🤝 In the subsequent sessions, both parties reached several consensuses on the implementation path of the cooperation plan and the next steps. This meeting marks a crucial step forward in Kelun Pharmaceutical's internationalization strategy. We will work closely with the EDB to jointly create a model of Sino-Singaporean biomedical cooperation!

We look forward to Kelun achieving even greater success in Singapore, this vibrant land of innovation! ✨

Kelun Singapore Board Meeting科伦新加坡董事会会议Following our recent engagement with representatives from the Singapore Economic ...
27/01/2026

Kelun Singapore Board Meeting
科伦新加坡董事会会议

Following our recent engagement with representatives from the Singapore Economic Development Board, Kelun Singapore convened a board meeting to further align on strategic priorities and regional development plans.
The discussion focused on governance, operational planning, and strengthening our long-term presence in Singapore and Southeast Asia.

继近期与新加坡经济发展局的深入交流后，科伦新加坡召开董事会会议，就战略重点与区域发展规划进行进一步对齐。
会议围绕公司治理、运营规划及在新加坡与东南亚的长期布局展开讨论，为稳健发展奠定基础。

Welcome & Exchange｜欢迎交流We were honored to welcome representatives from the Singapore Economic Development Board for an i...
19/01/2026

Welcome & Exchange｜欢迎交流

We were honored to welcome representatives from the Singapore Economic Development Board for an in-depth exchange at Kelun.
Discussions focused on industry development, innovation capabilities, and potential areas for future collaboration, reflecting our shared commitment to advancing cross-border cooperation.

我们非常荣幸接待新加坡经济发展局代表团到访科伦，开展深入交流。
双方围绕产业发展、创新能力及未来合作方向进行了充分探讨，共同展现了推动跨区域合作与高质量发展的愿景。

很多人以为衰老是某一天突然发生的——开始容易累、皮肤暗下来、恢复速度变慢。但真正的衰老，不是从外表开始的，而是从细胞失去保护、修复力下降开始的。有一种成分，身体其实很需要，但 18 岁之后就越来越少。它叫麦角硫因。它不是流行补剂，而是被科学...
07/11/2025

很多人以为衰老是某一天突然发生的——
开始容易累、皮肤暗下来、恢复速度变慢。

但真正的衰老，
不是从外表开始的，
而是从细胞失去保护、修复力下降开始的。

有一种成分，
身体其实很需要，
但 18 岁之后就越来越少。
它叫麦角硫因。

它不是流行补剂，
而是被科学研究了 100 多年、
被称为「长寿维生素」的细胞守护分子。

它的守护，体现在四个核心维度：
🛡️ 修护光损伤：减轻日晒引起的皮肤泛红与深层细胞损伤
🛡️ 清除自由基：对抗氧化应激，改善熬夜后的疲惫与精力不振
🛡️ 舒缓内在炎症：由内调节体质，缓解易敏状态
🛡️ 延缓肌肤老化：帮助维持胶原蛋白，减缓流失速度

——那些让你“皮肤状态下滑、精力不如从前”的根源，
正是它长期对抗的对手。

如果你也是第一次认识麦角硫因，
不妨收藏或标记这篇。
等你想从细胞层面找回状态，
会知道从哪里开始，找到科学的答案。

——
科伦新加坡 · 麦角硫因
从核心位置，做长久守护

#科伦麦角硫因 #麦角硫因新加坡 #天然抗氧化 #健康能量 #青春守护

🌿 科伦麦角硫因 | Kelun L-Ergothioneine自由基是能量代谢的自然产物，但当它过量时，会引发氧化应激，导致细胞受损、线粒体功能下降，进而让身体出现疲惫、暗沉与加速老化等迹象。🍄 L-Ergothioneine（麦角硫因）...
30/10/2025

🌿 科伦麦角硫因 | Kelun L-Ergothioneine

自由基是能量代谢的自然产物，
但当它过量时，会引发氧化应激，
导致细胞受损、线粒体功能下降，
进而让身体出现疲惫、暗沉与加速老化等迹象。

🍄 L-Ergothioneine（麦角硫因）

来自蘑菇的天然抗氧化成分，
有助于清除多余自由基、减轻氧化损伤，
增强细胞防御力，让身体焕发健康光彩。

📍科学高效 · 天然守护 · 焕活能量之源

#科伦麦角硫因 #麦角硫因新加坡 #天然抗氧化 #健康能量 #青春守护

🔬 科研突破，让健康更有底气麦角硫因因天然来源稀缺、提取工艺复杂，长期被誉为“生命黄金分子”。科伦集团以 “科伦锐康智擎AI生物合成系统” 为核心，成功攻克大健康重磅原料麦角硫因的规模化量产难题，让高纯度原料能够稳定量产，并应用于健康领域。...
29/10/2025

🔬 科研突破，让健康更有底气

麦角硫因因天然来源稀缺、提取工艺复杂，
长期被誉为“生命黄金分子”。

科伦集团以 “科伦锐康智擎AI生物合成系统” 为核心，
成功攻克大健康重磅原料麦角硫因的规模化量产难题，
让高纯度原料能够稳定量产，并应用于健康领域。

通过自主研发的 AI生物合成系统：
• 生产效率提升约30%
• 产品纯度高达99.99%

这项创新技术标志着科伦在健康科技领域的又一次重要进步，
也是将医药研发能力延伸至营养与健康产品的实践。

✨ 科伦药业新加坡
将持续以科学创新为核心，
让科研成果真正服务每一份健康。

#科伦健康新加坡　 #麦角硫因新加坡　 #科研创新　 #健康科技　 　 　

Address

290 Orchard Road, #06-11 Paragon
Singapore
238859

Telephone

+6596948888

Website

Alerts

Be the first to know and let us send you an email when 科伦药业新加坡 · Kelun Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to 科伦药业新加坡 · Kelun Pharma:

Shortcuts

Share

Category